Armie Margaret Lee

Armie Margaret Lee is a reporter covering private equity. Previously, she was at InvestmentWires, an online media company that focuses on the mutual fund and 401(k) industries. She has also covered real estate and banking for Miami Today and technology for Manila Times in the Philippines.

Recent Articles By The Author

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Updated interim data from a study of risdiplam were presented June 16 at the 22nd Annual SMA Researcher Meeting.

Mylan Slumps in After-Hours Trading on Generic Advair Update

Mylan Slumps in After-Hours Trading on Generic Advair Update

The drugmaker says the FDA will issue a complete response letter on June 27.

AT&T-Time Warner Ruling a Positive for Cigna-Express Scripts, CVS-Aetna Deals

AT&T-Time Warner Ruling a Positive for Cigna-Express Scripts, CVS-Aetna Deals

The ruling has a positive read-across for Cigna's pending acquisition of Express Scripts and CVS' deal for Aetna, according to Leerink's Ana Gupte.

Stryker Says Not in Talks to Buy Boston Scientific

Stryker Says Not in Talks to Buy Boston Scientific

The medical device firm issues an 8-K filing on the heels of a media report earlier this week that said it recently made a takeover approach to Boston Scientific.

KKR Buying Envision Healthcare for $9.9 Billion

KKR Buying Envision Healthcare for $9.9 Billion

The deal comes nearly two months after Envision completed the sale of its medical transportation unit to KKR-backed Air Medical Group Holdings.

Merck Higher on Lung Cancer Data

Merck Higher on Lung Cancer Data

The drugmaker's presentations at ASCO's annual meeting included data on Keynote-407, which Credit Suisse analyst Vamil Divan described as a 'clear positive.'

Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices

Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices

The Dublin-based drugmaker has wrapped up a strategic review of all its businesses, but says it's not pursuing a fire sale of its assets.

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks

The Summit, N.J.-based biotech firm also plans to enter into an accelerated share repurchase program to buy back $2 billion of stock.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.